

## Online supplementary tables

**Online Supplementary Table 1 Other baseline laboratory parameters**

	Group A	Group B	P value
	(N=3395)	(N=1755)	Group A vs B
	Mean (SD)	Mean (SD)	
AST (GOT) (IU/L)	26.1 (16.69)	27.2 (16.49)	0.048 *
ALT (GPT) (IU/L)	27.9 (23.53)	31.6 (26.11)	<0.001 ***
Red blood cell count ( $\times 10^4/\mu\text{L}$ )	448.3 (60.64)	462.5 (56.18)	<0.001 ***
Hemoglobin (g/dL)	13.83 (1.664)	14.17 (1.643)	<0.001 ***
Hematocrit (%)	41.00 (4.716)	41.75 (4.483)	<0.001 ***
Platelet count (/mm <sup>3</sup> )	21.38 (6.420)	21.62 (6.331)	0.279
White cell count (/ $\mu\text{L}$ )	6597.7 (5864.19)	6551.5 (5309.44)	0.813
Differential white blood cells /neutrophils (%)	58.79 (9.803)	58.29 (9.514)	0.334
Differential white blood cells /eosinophils (%)	2.99 (3.051)	2.74 (1.945)	0.047 *
Differential white blood cells /basophils (%)	0.61 (0.523)	0.64 (0.659)	0.369
Differential white blood cells /lymphocytes (%)	31.19 (8.807)	32.15 (8.969)	0.039 *
Differential white blood cells /monocytes (%)	5.96 (1.983)	5.72 (1.808)	0.014 *
Glycoalbumin (%)	19.51 (4.745)	20.60 (6.733)	0.009 **
Total protein (g/dL)	7.25 (0.759)	7.22 (0.601)	0.302
Blood urea nitrogen (mg/dL)	15.88 (5.100)	15.17 (4.936)	<0.001 ***
Uric acid (mg/dL)	5.42 (2.535)	5.36 (3.059)	0.575
Total bilirubin (mg/dL)	0.75 (0.512)	0.80 (0.748)	0.071
ALP (IU/L)	238.9 (88.77)	257.5 (99.02)	<0.001 ***
CK(CPK) (IU/L)	115.2 (90.21)	112.7 (85.86)	0.476
LDH (IU/L)	198.0 (52.24)	195.1 (46.21)	0.135
$\gamma$ -GTP (IU/L)	45.1 (56.04)	49.8 (64.77)	0.035 *
Amylase (IU/L)	77.2 (32.23)	71.1 (34.67)	0.002 **

Parameters were compared by t test.

ALP, alkaline phosphatase; ALT (GPT), alanine aminotransferase; AST (GOT), aspartate aminotransferase; CK (CPK), creatine kinase (creatine phosphokinase);  $\gamma$ -GTP, gamma-glutamyl transpeptidase; LDH, lactate dehydrogenase; SD, standard deviation.

**Online Supplementary Table 2 Summary of adverse events and serious adverse events**

Endpoint category	AEs	Group A	Group B	P value
		(N=3395)	(N=1755)	Group A vs B
		n (%)	n (%)	
Overall AEs		1449 (42.7%)	740 (42.2%)	0.744
Hypoglycemia		117 (3.4%)	53 (3.0%)	0.459
Pancreatitis		7 (0.2%)	3 (0.2%)	1.000
Skin disorders		215 (6.3%)	91 (5.2%)	0.106
	Eczema (including nummular or systemic)	55 (1.6%)	18 (1.0%)	0.105
	Pruritus	31 (0.9%)	15 (0.9%)	0.877
	Rash (including systemic)	23 (0.7%)	9 (0.5%)	0.576
	Urticaria	22 (0.6%)	18 (1.0%)	0.179
	Skin ulcer	10 (0.3%)	2 (0.1%)	0.241
	Erythema (including annular, multiforme or systemic)	10 (0.3%)	9 (0.5%)	0.232
	Skin exfoliation	3 (0.1%)	1 (0.1%)	1.000
	Bullous pemphigoid	3 (0.1%)	0 (0.0%)	0.556
	Photosensitivity disorder	2 (0.1%)	2 (0.1%)	0.609
	Pigmentation	1 (0.03%)	1 (0.1%)	1.000
	Alopecia	1 (0.03%)	0 (0.0%)	1.000
	Oculomucocutaneous syndrome (Stevens-Johnson syndrome)	0 (0.0%)	0 (0.0%)	NA
	Other: Skin papilloma	0 (0.0%)	3 (0.2%)	0.040 *
Infections		348 (10.3%)	181 (10.3%)	0.961
	Upper respiratory tract infection	110 (3.2%)	54 (3.1%)	0.802
	Pneumonia	45 (1.3%)	19 (1.1%)	0.509
	Cystitis	34 (1.0%)	15 (0.9%)	0.653
	Bronchitis	33 (1.0%)	13 (0.7%)	0.439
	Pharyngitis	25 (0.7%)	19 (1.1%)	0.204
	Enteritis infectious	21 (0.6%)	11 (0.6%)	1.000

	Herpes zoster	21 (0.6%)	8 (0.5%)	0.558
	Pyelonephritis	12 (0.4%)	7 (0.4%)	0.811
	Sinusitis	5 (0.1%)	3 (0.2%)	1.000
	Sepsis	5 (0.1%)	0 (0.0%)	0.173
	Tonsillitis	4 (0.1%)	4 (0.2%)	0.457
	Herpes virus infection (excluding Herpes zoster)	4 (0.1%)	1 (0.1%)	0.667
	Otitis media	3 (0.1%)	2 (0.1%)	1.000
	Urethritis	2 (0.1%)	2 (0.1%)	0.609
	Furuncle	1 (0.03%)	0 (0.0%)	1.000
	Other: Vulvovaginal candidiasis	0 (0.0%)	3 (0.2%)	0.040 *
Cancer		162 (4.8%)	62 (3.5%)	0.043*
	Lung cancer	32 (0.9%)	11 (0.6%)	0.262
	Large intestine carcinoma	25 (0.7%)	9 (0.5%)	0.468
	Gastric cancer	20 (0.6%)	8 (0.5%)	0.690
	Prostate cancer	17 (0.5%)	5 (0.3%)	0.368
	Hepatic cancer	13 (0.4%)	3 (0.2%)	0.291
	Thyroid cancer	10 (0.3%)	2 (0.1%)	0.241
	Breast cancer	5 (0.1%)	3 (0.2%)	1.000
	Pancreatic cancer	5 (0.1%)	2 (0.1%)	1.000
	Uterine cancer (cervical cancer, endometrial cancer)	3 (0.1%)	0 (0.0%)	0.556
	Other cancers	44 (1.3%)	27 (1.5%)	0.529
Others		1060 (31.2%)	564(32.1%)	0.507
	Renal and urinary disorders (SOC) <sup>a</sup>	78 (2.3%)	25 (1.4%)	0.036 *
	Iron deficiency anaemia	18 (0.5%)	2 (0.1%)	0.030 *
	Diabetes mellitus inadequate control	16 (0.5%)	17 (1.0%)	0.042 *
	Palpitations	5 (0.1%)	8 (0.5%)	0.044 *
	Heat illness	2 (0.1%)	5 (0.3%)	0.050 *
	Transient ischemic attack	2 (0.1%)	5 (0.3%)	0.050 *
	Cholangitis	1 (0.03%)	5 (0.3%)	0.020 *

	Gastric polyps	1 (0.03%)	5 (0.3%)	0.020 *
	Non-alcoholic steatohepatitis	1 (0.03%)	4 (0.2%)	0.049 *
	Hand fracture	0 (0.0%)	3 (0.2%)	0.040 *
<b>Serious adverse events</b>				
<b>Endpoint category</b>	<b>SOCs</b>	<b>n (%)</b>	<b>n (%)</b>	<b>Group A vs B</b>
Overall SAEs		495 (14.6%)	220 (12.5%)	0.046 *
Hypoglycemia		3 (0.1%)	0 (0.0%)	0.556
Pancreatitis		3 (0.1%)	3 (0.2%)	0.416
Skin disorders		3 (0.1%)	0 (0.0%)	0.556
Infections		71 (2.1%)	28 (1.6%)	0.240
Cancer		132 (3.9%)	48 (2.7%)	0.037 *
Other SAEs		348 (10.3%)	168 (9.6%)	0.463
	Blood and lymphatic system disorders	4 (0.1%)	1 (0.1%)	0.667
	Cardiac disorders	82 (2.4%)	35 (2.0%)	0.375
	Congenital, familial and genetic disorders	1 (0.03%)	0 (0.0%)	1.000
	Ear and labyrinth disorders	6 (0.2%)	2 (0.1%)	0.724
	Endocrine disorders	2 (0.1%)	1 (0.1%)	1.000
	Eye disorders	16 (0.5%)	10 (0.6%)	0.680
	Gastrointestinal disorders	44 (1.3%)	20 (1.1%)	0.692
	General disorders and administration site conditions	16 (0.5%)	4 (0.2%)	0.240
	Hepatobiliary disorders	24 (0.7%)	11 (0.6%)	0.859
	Immune system disorders	0 (0.0%)	1 (0.1%)	0.341
	Infections and infestations	15 (0.4%)	2 (0.1%)	0.070
	Injury, poisoning and procedural complications	50 (1.5%)	24 (1.4%)	0.806
	Investigations	5 (0.1%)	2 (0.1%)	1.000
	Metabolism and nutrition disorders	30 (0.9%)	10 (0.6%)	0.246
	Musculoskeletal and connective tissue disorders	22 (0.6%)	9 (0.5%)	0.704
	Neoplasms benign, malignant and unspecified (including cysts and polyps)	6 (0.2%)	9 (0.5%)	0.052

Nervous system disorders	52 (1.5%)	26 (1.5%)	1.000
Psychiatric disorders	5 (0.1%)	5 (0.3%)	0.324
Renal and urinary disorders	12 (0.4%)	3 (0.2%)	0.291
Reproductive system and breast disorders	4 (0.1%)	1 (0.1%)	0.667
Respiratory, thoracic and mediastinal disorders	10 (0.3%)	7 (0.4%)	0.610
Skin and subcutaneous tissue disorders	1 (0.03%)	1 (0.1%)	1.000
Surgical and medical procedures	26 (0.8%)	16 (0.9%)	0.625
Vascular disorders	10 (0.3%)	10 (0.6%)	0.157

All AEs were collected according to MedDRA version 15.1. AEs and SAEs were summarized for five major AE categories without defining limitations such as ‘symptomatic’ for hypoglycemia. AEs were also listed under ‘Other’ category only when significant between-group difference in their incidence was confirmed. ‘Other’ SAEs were summarized as those categorized in the individual MedDRA SOCs. Incidence (%) was calculated as a division of n for each AE category by either 3395 (Group A) or 1755 (Group B). P values were based on Fisher’s exact test.

<sup>a</sup> This SOC was listed because of a significant difference detected between the two groups, while no difference was observed for the individual AEs under the SOC.

AE, adverse event; NA, not applicable; SAE, serious adverse event; SOC, system organ class.

**Online Supplementary Table 3 Multivariate Cox regression analysis of cancer development**

Variable	Category	N	Patients with event	Univariate model (Cox regression)			Multivariate initial model with variables giving P<0.05 in univariate model			Multivariate final model after backward elimination with P<0.05		
				HR	95% CI	[P for variable] P for category	HR	95% CI	[P for variable] P for category	HR	95% CI	[P for variable] P for category
Whole population		5150	224	—	—	—	—	—	—	—	—	—
Group	Group A	3395	162	Reference	—	—	Reference	—	—			
	Group B	1755	62	0.736	(0.549, 0.987)	0.040*	0.836	(0.619, 1.128)	0.241			
Mode of study initiation	Start	1650	55	Reference	—	[0.009**]	Reference	—	[0.155]			
	Addition	1563	62	1.117	(0.777, 1.605)	0.552	1.045	(0.703, 1.554)	0.827			
	Switch	1937	107	1.586	(1.145, 2.195)	0.005**	1.344	(0.931, 1.940)	0.115			
Number of previous OHAs	0	1650	55	Reference	—	[0.216]						
	1	1549	74	1.380	(0.973, 1.956)	0.071						
	2	1196	60	1.426	(0.989, 2.056)	0.057						
	≥3	755	35	1.281	(0.838, 1.957)	0.252						

Number of baseline OHAs	1	2140	94	Reference	—	[0.748]						
	2	1641	72	0.958	(0.705, 1.302)	0.784						
	3	1022	46	0.978	(0.687, 1.392)	0.902						
	≥4	347	12	0.714	(0.392, 1.302)	0.272						
Age (years)	<65	2389	41	Reference	—	[<0.001***]	Reference	—	[<0.001***]	Reference	—	[<0.001***]
	≥65 and <75	1782	102	3.310	(2.304, 4.757)	<0.001***	3.167	(2.180, 4.602)	<0.001***	3.341	(2.319, 4.814)	<0.001***
	≥75	979	81	5.249	(3.605, 7.643)	<0.001***	5.086	(3.410, 7.585)	<0.001***	5.543	(3.775, 8.139)	<0.001***
Disease duration (years)	<1	827	34	Reference	—	[0.020*]	Reference	—	[0.081]			
	≥1 and <5	1188	32	0.611	(0.377, 0.990)	0.046*	0.579	(0.352, 0.952)	0.031*			
	≥5 and <10	1269	64	1.116	(0.736, 1.692)	0.604	0.875	(0.558, 1.373)	0.562			
	≥10	1866	94	1.128	(0.762, 1.670)	0.548	0.688	(0.443, 1.070)	0.097			
BMI (kg/m <sup>2</sup> )	<25	2753	141	Reference	—	[0.013*]	Reference	—	[0.645]			



	≥25	2391	83	0.665	(0.507, 0.873)	0.003**	0.876	(0.665, 1.156)	0.350			
	Unknown	6	0	<0.001	(<0.001, >999.999)	0.971	<0.001	(<0.001, >999.999)	0.972			
HbA1c (%)	<6.0	159	10	Reference	—	[0.237]						
	≥6.0 and <7.0	1146	56	0.722	(0.369, 1.416)	0.344						
	≥7.0 and <8.0	1780	83	0.668	(0.347, 1.287)	0.228						
	≥8.0	1294	46	0.544	(0.274, 1.077)	0.081						
	Unknown	771	29	0.516	(0.251, 1.060)	0.072						
Total cholesterol (mg/dL)	<220	2537	128	Reference	—	[0.065]						
	≥220	614	21	0.701	(0.442, 1.113)	0.132						
	Unknown	1999	75	0.739	(0.555, 0.982)	0.037*						
Smoking status	No history	2607	96	Reference	—	[0.001**]	Reference	—	[<0.001***]	Reference	—	[0.001**]
	Current smoker	1018	36	1.005	(0.685, 1.475)	0.979	1.444	(0.976, 2.137)	0.066	1.461	(0.987, 2.161)	0.058

Previous	1525	92	1.648	(1.238,	<0.001***	1.730	(1.298,	<0.001***	1.704	(1.279,	<0.001***
smoker				2.193)			2.304)			2.269)	

Variates included in the model were group, mode of study initiation (i.e. 'start', 'addition' and 'switch'), number of OHAs previously used, number of OHAs used at baseline, age, disease duration, BMI, HbA1c, total cholesterol, and smoking status.

BMI, body mass index; CI, confidence interval; HbA1c, hemoglobin A1c; HR, hazard ratio; OHA, oral hypoglycemic agent.

**Online Supplementary Table 4 Over-time changes in other related parameters**

Parameter	Group	Measurements/Changes <sup>a</sup>	Visit (year)							
			Baseline <sup>b</sup>	0.5	1.0	1.5	2.0	2.5	3.0	
Weight (kg)	A	Data fixed	3395	3358	3125	2974	2805	2631	2455	
		Measurements	N	2235	3067	2740	2559	2398	2219	1193
			Mean	65.11	64.78	64.96	64.99	65.06	65.07	65.50
			SD	14.227	14.066	13.968	13.992	13.860	13.902	14.041
		Changes	N	—	2036	1811	1698	1571	1452	1005
			Mean	—	-0.20	-0.17	-0.24	-0.34	-0.62	-0.81
			SD	—	3.095	3.357	3.781	3.900	4.277	4.341
	1-sample t test	—	P=0.003 **	P=0.034 *	P=0.010 *	P<0.001 ***	P<0.001 ***	P<0.001 ***		
	B	Data fixed	1755	1738	1619	1519	1427	1360	1280	
		Measurements	N	1084	1590	1431	1309	1242	1166	630
			Mean	67.72	67.66	67.62	67.31	67.09	66.97	66.34
			SD	14.814	14.987	15.141	14.897	14.767	14.714	14.713
		Changes	N	—	977	878	806	762	708	492
			Mean	—	-0.40	-0.37	-0.38	-0.50	-0.52	-0.92
SD			—	3.505	4.080	4.496	4.412	4.506	4.931	
1-sample t test	—	P<0.001 ***	P=0.007 **	P=0.017 *	P=0.002 **	P=0.002 **	P<0.001 ***			

Group A vs B		Measurements	2-sample t test	P<0.001 ***	P<0.001 ***	P<0.001 ***	P<0.001 ***	P<0.001 ***	P<0.001 ***	P=0.237
		Changes	2-sample t test	—	P=0.144	P=0.190	P=0.433	P=0.421	P=0.620	P=0.691
12-lead ECG	A	Examined		681 (100.0%)	624 (100.0%)	509 (100.0%)	410 (100.0%)	460 (100.0%)	375 (100.0%)	200 (100.0%)
			Normal	435 (63.9%)	403 (64.6%)	313 (61.5%)	240 (58.5%)	279 (60.7%)	221 (58.9%)	121 (60.5%)
			Of no clinical significance	196 (28.8%)	191 (30.6%)	180 (35.4%)	149 (36.3%)	164 (35.7%)	136 (36.3%)	69 (34.5%)
			Of clinical significance	50 (7.3%)	30 (4.8%)	16 (3.1%)	21 (5.1%)	17 (3.7%)	18 (4.8%)	10 (5.0%)
	B	Examined		408 (100.0%)	332 (100.0%)	232 (100.0%)	215 (100.0%)	231 (100.0%)	202 (100.0%)	102 (100.0%)
			Normal	289 (70.8%)	230 (69.3%)	152 (65.5%)	131 (60.9%)	154 (66.7%)	114 (56.4%)	55 (53.9%)
			Of no clinical significance	101 (24.8%)	89 (26.8%)	69 (29.7%)	80 (37.2%)	71 (30.7%)	81 (40.1%)	43 (42.2%)
			Of clinical significance	18 (4.4%)	13 (3.9%)	11 (4.7%)	4 (1.9%)	6 (2.6%)	7 (3.5%)	4 (3.9%)

		Group A vs B	$\chi^2$ test	P=0.032 *	P=0.337	P=0.220	P=0.141	P=0.281	P=0.551	P=0.419	
Total cholesterol (mg/dL)	A	Measurements	N	2104	2406	2234	2079	1962	1801	1126	
			Mean	188.0	182.5	182.0	181.2	182.2	182.1	181.6	
			SD	35.02	32.46	32.12	31.92	33.49	32.83	32.45	
		Changes	N	—	1915	1745	1616	1511	1385	946	
			Mean	—	-5.4	-5.9	-6.4	-5.4	-5.4	-5.1	
			SD	—	28.22	27.98	30.38	31.17	34.20	34.33	
		1-sample t test	—	P<0.001 ***	P<0.001 ***	P<0.001 ***	P<0.001 ***	P<0.001 ***	P<0.001 ***	P<0.001 ***	
		B	Measurements	N	1047	1276	1126	1052	994	897	524
				Mean	195.7	187.6	186.8	186.7	185.7	185.4	185.8
	SD			39.55	33.73	33.41	33.27	34.65	33.32	34.56	
	Changes		N	—	955	815	755	697	629	410	
			Mean	—	-6.7	-8.0	-7.1	-7.7	-7.7	-10.8	
			SD	—	31.22	32.74	34.42	33.94	34.21	37.41	
	1-sample t test		—	P<0.001 ***	P<0.001 ***	P<0.001 ***	P<0.001 ***	P<0.001 ***	P<0.001 ***	P<0.001 ***	
Group A vs B	Measurements		2-sample t test	P<0.001 ***	P<0.001 ***	P<0.001 ***	P<0.001 ***	P=0.007 **	P=0.015 *	P=0.017 *	

		Changes	2-sample t test	—	P=0.277	P=0.112	P=0.656	P=0.142	P=0.158	P=0.008 **	
HDL cholesterol (mg/dL)	A	Measurements	N	2677	3035	2780	2588	2447	2259	1442	
			Mean	54.7	54.4	54.6	54.7	54.8	55.0	55.2	
			SD	17.69	15.24	15.06	18.26	19.27	19.88	15.56	
		Changes	N	—	2543	2311	2146	2011	1856	1287	
			Mean	—	-0.2	-0.5	-0.3	-0.2	-0.2	0.2	
			SD	—	13.39	13.24	17.74	18.61	14.68	15.77	
				1-sample t test	—	P=0.351	P=0.098	P=0.462	P=0.703	P=0.548	P=0.673
	B	Measurements	N	1333	1573	1401	1300	1215	1124	693	
			Mean	54.1	54.8	55.2	55.5	55.0	54.6	55.4	
			SD	21.65	14.63	14.89	17.45	14.72	14.38	14.94	
		Changes	N	—	1258	1114	1025	956	886	599	
			Mean	—	0.7	1.0	1.3	0.5	0.0	0.5	
SD			—	18.51	19.11	23.43	21.20	22.02	26.25		
			1-sample t test	—	P=0.166	P=0.073	P=0.069	P=0.506	P=0.968	P=0.660	
Group A vs B	Measurements		P=0.358	P=0.330	P=0.261	P=0.194	P=0.759	P=0.493	P=0.759		

		Changes	—	P=0.097	P=0.020 *	P=0.051	P=0.444	P=0.774	P=0.805	
LDL cholesterol (mg/dL)	A	Measurements	N	2575	2930	2673	2524	2381	2201	1397
			Mean	109.3	104.5	103.8	102.8	103.2	102.6	101.5
			SD	31.13	28.32	27.11	28.09	27.64	27.23	26.96
		Changes	N	—	2432	2193	2041	1907	1766	1229
			Mean	—	-4.9	-5.5	-6.0	-5.6	-6.4	-7.1
			SD	—	25.06	26.11	27.97	28.86	30.11	31.43
	1-sample t test	—	P<0.001 ***	P<0.001 ***	P<0.001 ***	P<0.001 ***	P<0.001 ***	P<0.001 ***	P<0.001 ***	
	B	Measurements	N	1286	1538	1369	1277	1196	1116	663
			Mean	115.7	108.6	107.0	105.9	105.2	104.5	103.6
			SD	33.92	29.17	28.41	29.05	28.53	27.98	28.02
		Changes	N	—	1203	1060	975	906	843	563
			Mean	—	-7.3	-8.8	-9.8	-10.0	-9.9	-12.3
			SD	—	29.13	29.52	32.77	32.67	31.16	34.53
	1-sample t test	—	P<0.001 ***	P<0.001 ***	P<0.001 ***	P<0.001 ***	P<0.001 ***	P<0.001 ***	P<0.001 ***	
Group A vs B	Measurements		P<0.001 ***	P<0.001 ***	P<0.001 ***	P=0.001 **	P=0.040 *	P=0.060	P=0.103	
	Changes		—	P=0.014 *	P=0.002 **	P=0.002 **	P<0.001	P=0.006 **	P=0.002 **	

		***									
Fasting triglycerides (mg/dL)	A	Measurements	N	1809	2101	1927	1704	1629	1480	942	
			Mean	137.4	133.0	132.3	132.8	132.1	132.3	133.3	
			SD	85.19	83.98	92.28	97.66	88.57	87.33	87.57	
		Changes	N	—	1481	1287	1159	1076	969	689	
			Mean	—	-2.6	-1.6	-1.7	-1.8	-3.8	-2.3	
			SD	—	77.94	78.84	94.07	90.94	85.32	84.58	
		1-sample t test	—	P=0.208	P=0.477	P=0.541	P=0.521	P=0.171	P=0.482		
		B	Measurements	N	886	1099	992	863	856	771	437
				Mean	143.8	135.0	136.5	133.0	131.9	133.0	137.0
	SD			92.72	93.64	90.58	95.13	81.20	92.56	95.62	
	Changes		N	—	719	612	550	510	450	298	
			Mean	—	-7.0	-1.8	-7.9	-9.6	-9.0	-8.5	
			SD	—	80.15	86.05	88.46	76.17	100.08	85.99	
	1-sample t test		—	P=0.020 *	P=0.614	P=0.037 *	P=0.004 **	P=0.057	P=0.089		
	Group A vs B		Measurements		P=0.086	P=0.554	P=0.240	P=0.958	P=0.946	P=0.856	P=0.496
Changes				—	P=0.214	P=0.963	P=0.194	P=0.073	P=0.337	P=0.291	



<sup>a</sup> Changes mean those from baseline measurements and were calculated for the patients with measurements available at baseline and the predefined visit.

<sup>b</sup> The mean baseline values in this supplementary table may be somewhat different from those seen in table 1. This is because table 1 presents mean values calculated for the SAS patients with measurements, while supplementary table 4 presents values calculated for the SAS patients for whom measurements were performed within the study protocol-defined time window i.e. Day -92 through Day 31 (as baseline) relative to Day 0 (i.e. the date of ‘start’, ‘addition’ or ‘switch’), also explaining apparent differences in N between the two tables.

ECG, electrocardiography; HDL, high density lipoprotein; LDL, low density lipoprotein.